References
- Andersson T, Miners JO, Veronese ME, Birkett DJ. 1994. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. British Journal of Clinical Pharmacology 37:597-604.
- Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, Chenery RJ. 1995. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270.
- Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, Kaye SB, Gianni L, Harris A, Bjork T, Averbuch SD, Feyereislova A, Swaisland H, Rojo F, Albanell J. 2002. Phase I safety, pharmacokinetics, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. Journal of Clinical Oncology 20:4292-4302.
- Ciardiello F, Tortora G. 2002. Anti-epidermal growth factor receptor drugs in cancer therapy. Expert Opinion on Investigational Drugs 11:755-768.
- De Wildt SN, Kearns GL, Leeder JS, Van den Anker JN. 1999. Cytochrome P450 3A. Ontogeny and drug disposition. Clinical Pharmacokinetics 37:485-505.